Assessing the feasibility of developing Ai2's novel anti-infective peptide technology for topical anti-fungal applications.

AI2是一家总部位于英国的生物技术公司，专门从事新型抗感染多肽技术，将强大的抗菌功效与出色的安全性结合在一起。AI2目前正在研究该技术的抗真菌效果，以确定作为抗真菌药物开发的可行性。局部真菌感染是一种常见的日益严重的健康问题，会给患者造成不适和痛苦，并可能导致潜在的致命全身感染。目前可用的治疗方法存在治疗时间长、产生抗药性等显著缺点，因此需要一种更有效的药物。该项目旨在确定选定的多肽对相关生物的有效性以及它们与人体组织的安全性和兼容性。这将导致AI2产生一个数据组合，证明进一步开发我们的技术作为抗真菌药物的可行性。

Ai2 is a UK-based biotechnology company specialising in novel anti-infective peptide technology combining potent antibacterial efficacy with excellent safety. Ai2 is now researching the antifungal efficacy of the technology to determine the feasibility of development as an antifungal agent. Topical fungal infections are a common and increasing health concern that cause discomfort and distress to patients and can lead to potentially fatal systemic infections. The currently available treatments have significant drawbacks including lengthy treatment time and resistance generation, therefore a more effective agent is needed. This project aims to establish the efficacy of selected peptides against relevant organisms and their safety and compatibility with human tissue. This would result in Ai2 generating a data portfolio that demonstrates the feasibility of developing our technology as an antifungal agent further.